Related Experiment Video
Updated: Dec 13, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Clinically complete response to abiraterone acetate in a patient with metastatic castration-resistant prostate cancer
Yoshinori Yanai1, Takeo Kosaka1, Hiroshi Hongo1
1Department of Urology Keio University School of Medicine Tokyo Japan.
Introduction:
Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration-resistant prostate cancer.
Case Presentation:
A 62-year-old patient with a bone metastatic castration-resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a day along with 10 mg prednisone. In spite of castrate testosterone level, the laboratory test showed a relatively high level of serum testosterone, which was 21 ng/dL. Within 6 months, the patient achieved a complete prostate-specific antigen response. Follow-up bone scintigraphy demonstrated no area of intense uptake. He had a history of hyperlipidemia and was started on atorvastatin at home just after starting abiraterone acetate.
Conclusion:
This report is a rare case of a clinically complete response to abiraterone acetate in a patient with metastatic castration-resistant prostate cancer.
